Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma

NCT07204262 · clinicaltrials.gov ↗

COMPLETED

Status

379

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

COMBINATION_PRODUCT: Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)

Sponsor

Xu Yong, MD